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Abstract
Introduction: GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in 
their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between 
breast cancer patients (BC) and healthy volunteers (HV).
Methods: An IRB approved prospective study enrolled 189 stage 1–4 BC patients and 18 HV. GP88 serum concentration was   determined 
by immunoassay.
Results: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1–3 and 45.3 + 23.3 ng/ml 
(P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor 
grade, ER, PR and HER-2 expression.
Conclusion: These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, 
  monitoring and follow up of BC.
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Introduction
Breast  cancer  (BC)  is  the  most  common  type  of 
cancer diagnosed in women in the US.1 The major-
ity of patients are diagnosed with early stage disease 
but many will develop systemic recurrence later on 
therefore the value of serial monitoring for recurrence 
of breast cancer with circulating tumor markers is of 
importance. Efforts to identify such serum biomark-
ers in BC have largely been unsuccessful and are best 
represented  by  the  development  of  immunoassays 
for  CA15-3,  CA27-29  and  carcinoembryonic  anti-
gen (CEA) to be utilized for monitoring of patients 
with early and advanced breast cancer.2,3 The CEA 
blood test measures the level of the antigen CEA by a 
sandwich enzyme linked immunoassay. CA15-3 and 
CA27-29 tests measure the serum level of a mucin-
like membrane glycoprotein (MUC-1) that is shed 
from tumor cells into the bloodstream. The CA 15-3 
epitope is recognized by two monoclonal antibodies 
in a double-determinant or sandwich immunoassay. 
The CA27-29 is a one epitope antibody test gener-
ated against MUC-1 protein. It is well established that 
75% to 90% of patients with metastatic breast can-
cer will have elevated MUC-1 levels. Many studies 
have demonstrated that a rising CA15-3 or CA27-29 
level can detect recurrence after primary treatment. 
Thus, tests measuring MUC-1 have been used in the 
management  of  patients  with  breast  cancer.4,5  Hou 
et al2 showed that in patients with metastatic breast 
cancer the sensitivity and specificity was 85.7% for 
CA27-29, 82.8% for CA15-3 and 62.8% for CEA, 
respectively.  In  addition  patients  had  significantly 
higher levels of CA27-29 than CEA, but they were 
similar to CA15-3 suggesting that CA27-29 is more 
sensitive  and  specific  than  CEA,  but  is  similar  to 
CA15-3 for metastatic breast cancer detection and 
monitoring.
In another study, patients with hormone (HR) sen-
sitive and HER2 negative tumors were more likely to 
have elevated CA15-3 level at the time of diagnosis 
of metastatic disease than patients with other tumor 
types, 69% for HR+ Her2- primary tumors, 56% of 
HR+ Her2+++, 46% of HR- Her2+++ and 41% for 
triple-negative cases (P = 0.003).6 Safi et al7 assessed 
CA15-3  serum  levels  preoperatively  in  N  =  1342 
patients with benign breast conditions and various 
malignancies. CA15-3 levels were found to be over 
50 U/ml in 0%, 2%, 13%, and 73% of the patients 
with stages 1, 2, 3, and 4 breast cancer respectively. 
Others showed that CA15-3 levels were highest in 
patients with liver metastases and increasing num-
bers of metastatic sites and that the increased CA15-3 
concentration usually preceded the clinical diagnosis 
of the relapse with the median lead time of 9 months 
(range: 1–40) in 72.4% of patients with distant metas-
tases due to breast carcinoma.5 The low detection rate 
in early stage BC has precluded the routine use of 
CA15-3 for screening for breast cancer recurrence, 
even though CA15-3 is utilized to monitor the effec-
tiveness of treatments for metastatic BC in addition to 
imaging studies and clinical symptoms.
Other recent serum-based tumor markers in BC, 
also measured by enzyme immunoassays, include the 
plasminogen  activator  (PA)  system  which  is  com-
prised of the 2 serine proteases, urokinase PA (uPA) 
and tissue PA (tPA), the 2 serpin inhibitors, PAI-1 
and  PAI-2  and  the  uPA  receptor  (uPAR;  CD87). 
High levels of uPA, PAI-1, uPA-PAI-1 complex and 
uPAR in BC tissue are associated with poor progno-
sis, while high levels of tPA or PAI-2 correlate with 
good prognosis.10 Measurements of the extracellular 
domain of Her-2 (HER2- ECD) have also been found 
to be prognostic for predicting response to anti-Her2 
therapy and monitoring recurrence.11 Our laboratory 
is  focused  on  characterizing  functional  biological 
markers of breast cancer with a particular attention to 
proteins produced by the cancer cells and released in 
the circulation. Such proteins’ function is to stimulate 
tumor growth and survival or inhibit apoptosis which 
often results in acquisition of resistance to therapeutic 
interventions. Such targets would be ideal as tissue-
based or serum-based biomarkers as well as a base for 
development of targeted therapy. One such marker is 
the autocrine growth/survival factor PC cell derived 
growth  factor  (PCDGF  also  called  GP88).  GP88 
(also known as progranulin, acrogranin or granulin-
epithelin precursor) is the largest member of a unique 
family of cysteine-rich polypeptides growth modula-
tors that include the 6 kDa epithelins or granulins.12,13 
The 88 kda glycoprotein contains a 63 kDa core pro-
tein with a 17 amino-acid signal peptide for targets 
GP88 for secretion. Our laboratory was the first to 
demonstrate the biological activity of 88 kDa GP88 
as a growth promoter for tumorigenic cells including 
human breast cancer cells.14,15 Others later demon-
strated growth-promoting activity of the precursor for Circulating gP88 (progranulin) in breast cancer patients serum
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other mesenchymal and epithelial cells as well as for 
pre-implantation embryos.16–18 The 88 kDa protein has 
been shown to play a role in tumorigenesis, includ-
ing stimulation of proliferation, survival, migration, 
angiogenesis  invasion  and  matrix  metallo-protease 
activity.19 In addition, in normal tissues, it plays a 
role in wound healing and in inflammation.20,21 The 
pathways involved in GP88 signaling include both 
the mitogen-activated protein kinase (MAP Kinase 
Erk 1/2), phosphatidylinositol 3-kinase (PI-3 Kinase), 
and focal adhesion kinase (FAK), leading to the acti-
vation of the cell cycle regulatory proteins Cyclin D1 
and Cyclin B.15,17,22–25
Screening  of  human  breast  adenocarcinoma  cell 
lines indicated that GP88 was expressed in correlation 
with tumorigenic properties. Conversely, inhibition of 
GP88 expression by antisense cDNA transfection in 
ER- human breast carcinoma resulted in a greater than 
90%  reduction  of  tumor  incidence  and  tumor  size 
when injected in nude mice,15 implicating GP88 as a 
major factor in the maintenance of tumor phenotype. 
In ER-positive (ER+) cells, GP88 expression was asso-
ciated with the acquisition of resistance to the to the 
anti-estrogen Tamoxifen both in vitro and in vivo.26,27 
In addition, GP88 overexpression has been associated 
with resistance to Trastuzumab and to doxorubicin.28,29 
Pathological studies in paraffin embedded human BC 
biopsies indicated that GP88 was overexpressed in 
80%  of  invasive  ductal  carcinoma,  where  it  corre-
lated with clinical parameters of poor prognosis such 
as tumor grade, p53 expression and Ki67 index.26 In 
contrast, normal mammary tissues and benign lesions 
were negative for GP-88 expression.26
Based on these properties and since GP88 is over-
expressed in BC tissues and is targeted for secretion, 
we elected to conduct a clinical correlation study to 
determine whether GP88 can be measured/detected 
in blood samples from healthy volunteers (HV) and 
BC patients and if the measured level is statistically 
elevated in BC patients compared to HV. We also 
planned to look at the accepted BC prognostic factors 
such as age, stage, ER, PR, HER2 and tumor grade in 
relation to the GP88 serum level.
Materials and Methods
A  prospective,  IRB  approved  blood  sampling  pro-
tocol was established at the University of Maryland 
Marlene  and  Stewart  Greenebaum  Cancer    Center 
(UMGCC) and enrolled HV and stage 1–4 BC patients 
undergoing therapy or coming for routine follow-ups 
to the UMGCC’s Breast Cancer Clinic. HV and BC 
patients were sampled once to test the hypothesis that 
the serum GP88 can be measured via our method. 
Study eligibility criteria included histologically con-
firmed diagnosis of BC, age greater than 18, stage 
1–4, status post lumpectomy or   mastectomy. Stage 
4  patients  were  sampled  during  systemic  therapy 
  (chemotherapy, hormonal therapy or HER2 targeted 
therapy). The majority of early stage patients were 
sampled  after  completion  of  adjuvant/  neoadjuvant 
chemotherapy but while still receiving adjuvant hor-
monal therapy if indicated based on tumor charac-
teristics. Patients with stage 4 BC were eligible to 
participate in this study irrespective of the number of 
prior therapies received for treatment of MBC.
Healthy volunteers had to be more than 18 years of 
age and without current or prior history of malignancy 
and  were  required  to  sign  informed  IRB  approved 
consent.  For  patients  actively  receiving  adjuvant 
  chemotherapy, blood samples were drawn before the 
  chemotherapy was given on the day of treatment. The 
majority of early stage BC patients in our study were not 
sampled while receiving active adjuvant chemotherapy 
but while they were coming for routine follow-up visits 
to the oncology clinic after completion of active che-
motherapy. Non fasting blood was   collected into serum 
preparation tubes (BD   Diagnostics) at the UMGCC 
and immediately transferred on ice,   unprocessed; to 
A&G  Pharmaceutical  in  Columbia,  Maryland  for 
serum  preparation  and  analysis  of  the  GP88  serum 
  levels. Password protected clinical database of study 
  participants was established at the UMGCC under the 
UM IRB and HIPAA guidelines. Participants (HV and 
BC patients) were assigned study numbers and these 
were used for further analysis of the GP88 levels of 
study participants at AG Pharmaceutical. The GP88 
levels were reported back to the principal investigator 
at the UMGCC who then collected this information 
prospectively together with other patient and tumor 
specific  information.  The  statistical  analysis  of  the 
data was performed by an independent   University of 
  Maryland faculty member statistician.
serum Gp88 eIA
Whole blood samples received from UMGCC were 
processed, spun at 3000RPM for 10 minutes to   collect Tkaczuk et al
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serum.  Once  aliquoted,  serum  samples  were  kept 
at -80 °C before assaying for GP88. Measurement 
of GP88 levels in serum was carried out in triplicates 
using a GP88 sandwich enzyme immunoassay (EIA) 
kit developed by A & G Pharmaceutical, comprising 
a combination of capture and detection anti-human 
GP88 antibodies with increasing amounts of human 
GP88 used for calibration curve. Serum calibrators 
consisting of human sera spiked with known amount 
of GP88 were also used as internal controls in the 
assays; specifically, 96-well plates were coated with 
1µg/well  of  capture  anti-GP88  mouse  monoclonal 
antibody. After washing, serum samples or standard 
human GP88 were incubated for 2 hours at 37 °C. 
Following washing, 100 µl of detecting rabbit anti-
human GP88 antibody was added and incubated at 
37 °C for 1 hr. Following washing, HRP-conjugated 
goat  anti-rabbit  secondary  IgG,  was  added.  After 
1 hr of incubation, plates were washed and 100 µl of 
HRP substrate was added. OD at A620 was read with 
a microtiter plate reader. Amount of GP88 in serum 
samples from BC and HV was calculated from the 
standard human GP88 curve.
statistical Analysis
Descriptive  statistics  were  used  to  summarize 
patients’  characteristics.  These  were  reported  by 
proportions  (for  categorical  variables)  and  median 
(range) for continuous variables. The mean level of 
GP88 among HV and different stages of BC patients 
were compared using Analysis of Variance (ANOVA) 
and T test. The  associations  of  GP88  with  patient 
and tumor characteristics were assessed by t test or 
ANOVA. A Receiver Operating Characteristic (ROC) 
Curve was generated by plotting the sensitivity (the 
true positive rate) versus 1-specificity (the false posi-
tive rate) using GP88 cutoffs to classify breast cancer 
patients (BC) versus healthy volunteers (HV).
Results
Patient characteristics
The  demographics  and  clinico-pathological param-
eters of the 189 BC patients enrolled in this study 
are as follows: median age is 51, (age ranging from 
29 to 86); 56% of participants were aged $ 50. Of 
interest, our clinical trial cohort had an almost equal 
representation  of African American  and  Caucasian 
patients (48.7% and 48.1% respectively), well within 
the ethnic distribution of the population of Baltimore 
and the State of   Maryland. The majority of patients 
had invasive ductal carcinoma and 50% were lymph 
node (LN) negative and had tumors ,2 cm in diam-
eter while 28% had tumors 2–5 cm in diameter at 
diagnosis; 54% of participants were stage 1 and 2 and 
46% stage 3 and 4; 57% of patients were ER-positive 
and 46% PR-positive; 63% were HER2/neu negative, 
40% of patients had grade 3 tumors (Table 1).
Gp88 Level in serum of Breast  
cancer patients
We determined the serum GP88 level of BC patients 
and HV by sandwich EIA as described in the material 
and methods section. The enrollment of 18 healthy 
volunteers at the University of Maryland under the 
same IRB protocol used to enroll BC patients allowed 
us to establish a baseline serum GP88 level. Breast 
cancer patients were stratified in two categories: early 
stage (patients with stage 1, 2 and 3 disease) and stage 
4 or metastatic patients. GP88 level was measured 
in triplicates for each subject enrolled in the study. 
These values were then used to calculate mean and 
median values for subjects in the three groups: HV, 
early stage BC patients (stage 1, 2, and 3) and BC 
patients stage 4, respectively (Table 2).
As shown in Table 2, GP88 was measurable in the 
serum of HV and BC patients. The mean level of GP88 
for healthy volunteers was 28.7 ng/ml ± 5.8 ng/ml. For 
stage 1–3 BC patients, mean GP88 serum level was 
40.7 ± 16.0 ng/ml whereas it was 45.3 ± 23.3 ng/ml 
in stage 4 BC patients.
Statistical analysis of the results in Table 2 indicated 
that serum GP88 values were significantly elevated 
in both early stage (P = 0.007) and stage 4 patients 
(P  =  0.0007)  when  compared  to  the  GP88  serum 
level of healthy subjects. In addition, as shown in 
Figure 1, the range of GP88 values was much larger 
in BC patients than in healthy individuals reaching 
100 ng/ml for stage 1–3 patients and 158 ng/ml in 
stage 4 patients when compared HV where the high-
est values was 39 ng/ml.
No statistically significant difference in the mean 
of serum GP88 level was observed between the early 
stage and late stage disease groups. We then examined 
the possible association between patients GP88 serum 
level and their clinico-pathological parameters such 
as  age,  race,  lymph  node  status,    steroid    receptor Circulating gP88 (progranulin) in breast cancer patients serum
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Table 1. Breast cancer patient characteristics (n = 189).
characteristic no. of patients Median (range) 
or percent
Age 51 (29–86)
Age group (%) ,50 
$50
83 
106
43.9 
56.1
Race (%) Caucasian 
African American 
Other races
91 
92 
6
48.1 
48.7 
3.2
Stage (%) 1 
2 
3 
4
48 
52 
26 
63
25.4 
27.5 
13.8 
33.3
eR (%) Positive 
negative 
Unknown
109 
69 
11
57.7 
36.5 
5.8
PR (%) Positive 
negative 
Unknown
88 
89 
12
46.6 
47.1 
6.3
heR2 (%) Positive 
negative 
Unknown
34 
119 
36
18.0 
63.0 
19.0
grade (%) 1 
2 
3 
Unknown
30 
43 
76 
40
15.9 
22.7 
40.2 
21.2
Tumor type (%) Ductal 
Lobular 
Other*
152 
18 
19
80.4 
9.5 
10.1
Lymph node status 
(Stage 1–3 patients)
negative 
Positive 
Unknown
63 
45 
18
50.0 
35.7 
14.37
Tumor size (cm) 
Stage 1–3 patients
,2 cm 
2–5 cm 
.5 cm 
Unknown
63 
36 
12 
15
50.0 
28.6 
9.5 
11.9
note: *Other includes: medullary, mucinous, tubular, colloid, and unknown.
Abbreviations: eR, estrogen receptor; PR, Progesterone Receptor; her-2, human epidermal growth factor receptor-2.
Table 2. Comparison of mean serum gP-88 level in breast cancer patients by stage with healthy volunteers (hV).
Group Median Gp88 (range) 
ng/ml
Mean Gp-88 (±sD) 
ng/ml
P-value*
hV 28.4 (16.6–38.2) 28.7 (±5.8) nA
BC Stage 1–3 38.7 (6.4–100.0) 40.7 (±16.0) 0.007
BC Stage 4 39.9 (9.8–158.4) 45.3 (±23.3) 0.0007
note: *P values are computed based on t tests.
expression,  (ER  and  PR),  Her-2  expression,  and 
tumor grade. No statistical correlation was observed 
between GP88 level and these parameters (Table 3).
Discussion
Glycoprotein GP88 (progranulin, PCDGF) is a growth 
and survival factor that has been shown to play an 
important role in breast cancer tumorigenesis.20,21 We 
previously showed that GP88 can be measured in 
breast cancer tumor tissue by immunohistochemistry 
staining with an anti-human GP88 antibody devel-
oped in our laboratory. These data showed that GP88 
was expressed at higher level in breast cancer tis-
sues (invasive ductal carcinoma) when   compared to Tkaczuk et al
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normal mammary tissue.30 In addition, GP88 tumor 
overexpression is associated with worse outcomes 
(disease-free survival and overall survivals) in early 
stage BC patients   (Serrero et al manuscript in prepa-
ration). We established an IRB approved prospec-
tive blood sampling study to examine by sandwich 
EIA the level of serum GP88 in BC patients and in 
Table 3. Association of serum gP-88 levels with patient and tumor characteristics.
characteristic Median (range) 
ng/ml
Mean Gp88 
ng/ml
P-value*
Age 
  ,50 
  $50
 
37.8 (9.8–105.8) 
39.5 (6.4–158.4)
 
40.2 
43.8
 
0.19
Race 
  Caucasian 
  African American
 
38.3 (9.8–100.0) 
39.4 (6.4–158.4)
 
40.7 
43.8
 
0.27
eR 
  + 
  -
 
38.0 (15.1–158.4) 
38.7 (6.4–105.8)
 
42.0 
42.2
 
0.96
PR 
  + 
  -
 
37.9 (15.1–85.3) 
38.7 (6.4–105.8)
 
41.4 
41.4
 
1.0
heR2 
  + 
  -
 
37.4 (9.8–85.3) 
39.0 (6.4–105.8)
 
41.0 
40.9
 
0.99
grade 
 1  
 2  
 3
 
41.2 (15.1–158.4) 
39.0 (16.1–100.0) 
37.9 (6.4–105.8)
 
45.6 
41.8 
40.3
 
0.45
notes: *P values are computed based on t tests for all comparisons except for comparison among grades, which is based on analysis of variance.
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Figure 1. Comparison of the gP88 level in healthy volunteers (hV) and 
breast cancer patients separated by stages (Stage 1–3) and stage 4. 
gP88  serum  levels  in  healthy  volunteers  and  breast  cancer  patients 
stage 1–3 and stage 4 were represented by box and whisker plots. The 
mean is represented by a + sign. The median is represented by the line 
inside the box. The bottom and top of the box represent the 25th and 
75th percentiles. The vertical line extends to the minimum and maximum 
data values.
healthy volunteers with study participants being sam-
pled once. We showed that by our technique, GP88 is 
measurable in the non-fasting blood samples of HV 
and patients with stage 1–4 BC. A baseline serum 
GP88 level was established for healthy volunteers. 
When compared to this baseline, BC patients with 
both early and late stage diseases have a statistically 
significant  increase  in  the  serum  GP88  level. An 
analysis of ROC curve for control and BC patients 
GP88 values indicated that by using a GP88 cut off 
value of 30.4 ng/ml, specificity and sensitivity of the 
assay were 72% which is in line with the sensitivity 
of CA15-3 and CA27-29.7
We found a statistically significant difference in 
the serum levels of GP88 between individuals without 
history of breast cancer and BC patients regardless of 
the stage. We did not however find a statistically sig-
nificant difference in the serum GP88 level between 
patients with different stages of BC and this could 
certainly be explained by the fact that patients were 
sampled at different points of their treatment for BC 
as described in the method section. The purpose of 
the investigation initially was to establish that GP88 
can be detected and measured by our assay and we 
were able to establish this in our study. Interestingly 
we found that GP88 serum level was elevated in early 
stage BC patients and this makes this test attractive Circulating gP88 (progranulin) in breast cancer patients serum
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for further investigation in more structured prospec-
tive protocol in this patient population. The objective 
of the present study was not to differentiate between 
the stages or other prognostic factors for early stage 
BC since patients were not enrolled at the time of ini-
tial diagnosis of early or advanced BC. Sixty seven 
percent of participants had early stage BC and were 
sampled after completion of lumpectomy or mastec-
tomy surgery. We did not find statistically significant 
correlation between the GP-88 serum level and the 
tumor expression of ER, PR, HER2 and tumor grade. 
In addition age and race did not seem to have an effect 
on the level of the GP-88.
The  fact  that  there  was  no  significant  differ-
ence  in  GP88  values  between  patients  aged  ,  50 
and $50 years old suggests that GP88 measurement 
can be used in both pre- and postmenopausal women. 
Similarly, the lack of difference in GP88 values in 
African-American  and  Caucasian  would  support 
the wide use of GP88 measurement across diverse 
breast cancer populations. Concerning tumor charac-
teristics, our previous IHC study showed that GP88 
was expressed in both ER positive and ER negative 
tumors.  Additionally,  the  tissue  based  study  indi-
cated that GP88 was an independent biomarker from 
  Her-2.30 These results could possibly explain why we 
did not find any difference in serum GP88 level with 
ER, PR and Her-2 status.
Our findings suggest that subsequent studies to 
explore the GP88 serum level testing as a screen-
ing blood test for breast cancer in otherwise healthy 
population  of  women  are  warranted.  Our  results 
also support further studies in breast cancer patients 
to  examine  the  correlation  of  the  serum  level  of 
GP88 with disease-free and overall survival param-
eters  and  with  respect  to  other  tumor  character-
istics (ER, PR, HER2, tumor grade, size and LN 
status) in patients enrolled at the initial diagnosis. 
Further studies of the association of the serum level 
of  GP-88  and  the  response  to  systemic  therapy, 
time to progression and survival in patients with 
advanced breast   cancer are also warranted based on 
our initial results. Our efforts are currently focused 
on the prospective serial blood sampling study in 
patients with advanced breast cancer. In addition 
we are prospectively sampling patients with early 
stage breast cancer who are currently undergoing 
therapy and post therapy for 2–3 years when the 
risk of recurrence is the highest. We believe that 
this approach is more likely to show the correla-
tion of the GP-88 level with the various BC clinico-
pathologic prognostic factors.
In summary, this study established that GP88 can 
be measured successfully in the blood of HV and BC 
patients and the fact that GP88 expression can also be 
measured in tumor tissue and is considered a negative 
prognostic factor makes it an interesting biomarker to 
study further in different clinical settings.
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